Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida,Masashi Yoneda,Katsutoshi Tokushige,Miwa Kawanaka,Hideki Fujii,Masato Yoneda,Kento Imajo,Hirokazu Takahashi,Yuichiro Eguchi,Masafumi Ono,Yuichi Nozaki,Hideyuki Hyogo,Masahiro Koseki,Yuichi Yoshida,Takumi Kawaguchi,Yoshihiro Kamada,Takeshi Okanoue,Atsushi Nakajima,Japan Study Group Of Nafld Jsg-Nafld
DOI: https://doi.org/10.3390/ijms21061907
2020-03-11
Abstract:Liver-related diseases are the third-leading causes (9.3%) of mortality in type 2 diabetes (T2D) in Japan. T2D is closely associated with nonalcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to hepatocellular carcinoma (HCC) and hepatic failure. No pharmacotherapies are established for NASH patients with T2D. Though vitamin E is established as a first-line agent for NASH without T2D, its efficacy for NASH with T2D recently failed to be proven. The effects of pioglitazone on NASH histology with T2D have extensively been established, but several concerns exist, such as body weight gain, fluid retention, cancer incidence, and bone fracture. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and NAFLD (LEAN study, LEAD trial, and E-LIFT study). Among a variety of SGLT2 inhibitors, dapagliflozin has already entered the phase 3 trial (DEAN study). A key clinical need is to determine the kinds of antidiabetic drugs that are the most appropriate for the treatment of NASH to prevent the progression of hepatic fibrosis, resulting in HCC or liver-related mortality without increasing the risk of cardiovascular or renal events. Combination therapies, such as glucagon receptor agonist/GLP-1 or gastrointestinal peptide/GLP-1, are under development. This review focused on antidiabetic agents and future perspectives on the view of the treatment of NAFLD with T2D.